Pilot and Exploratory Studies Core (PESC). This Core, led by Robert Clark, MD, and Alfred Fisher, MD, PhD, seeks to draw investigators into aging research relevant to the theme of the San Antonio OAIC and to promote early stage research that will set the stage for the development of both larger definitive studies and successful grant applications to continue the research project. To advance these goals the core leadership seeks the creation of novel aging research, and manages the application, review, selection, monitoring, and subsequent tracking of pilot proposals.
The PESC program addresses a critical area within the overall goals of the San Antonio OAIC – the development, testing, and validation of interventions proposed to enhance healthy aging and prevent or slow the progression of aging-associated processes and diseases, using both marmoset models and clinical studies. This overall goal capitalizes on rapidly accumulating data regarding the effects of pharmacologic and non-pharmacologic (e.g. stem cells, gene therapy) interventions on healthspan and lifespan in model organisms. The PESC, and the overall San Antonio
OAIC, will move these advances toward clinical use to
improve the health, quality of life, and independence of older Americans.
What types of studies does the PESC fund? In keeping with the overall emphasis of the OAIC, the PESC will support studies in marmosets and human subjects. Many of the studies supported will focus on pharmacologic interventions using compounds already in clinical use for other indications. However, we will also consider new molecular entities, stem cell, and gene therapy approaches, and other novel approaches to improve the health and functioning of older people based upon emerging clinical or basic science research.
Pilot Study Announcements and Applications
Rapid Response Pilot Program
We are soliciting applications for our new Rapid Response Pilot Grants Program for aging-related basic, clinical and translational research. Award size will range from $1,000 to $10,000, dependent on scope of work. In keeping with the overall emphasis of the SA OAIC, the PESC will support studies in either marmosets or human subjects, focusing especially on pharmacologic interventions using compounds already in clinical use for other indications. However, we will also consider new molecular entities, stem cell, and gene therapy approaches, and other novel approaches to improving the health and functioning of older people, based upon emerging clinical or basic science research.
A “rolling applications process” will be used. Applications will be accepted on a rolling basis until allocated funds for this program have been spent. Please see the program description and application requirements at the upper right of this page.
PESC Pilot Program
The application period for the 2017 PESC pilot program has closed, and funded projects will be announced imminently. You may view the 2017 RFA on the upper right of this page for information purposes; the 2018 RFA will be released in Fall 2017.
SNPRC-OAIC Joint Pilot Grant
The application period for the Southwest National Primate Research Center (SNPRC) and the OAIC joint pilot grant for projects using nonhuman primates in translational studies of aging is closed, and the recipient will be announced later this spring. The Joint SNPRC-Pepper Center RFA on the upper right is provided for information purposes.
Current Pilot Studies (PES) include:
PES-3: “Metformin for preventing frailty in high-risk older adults”
Investigators: Sara Espinoza*, MD (PI); Chen-Pin Wang*, PhD (Co-PI); Carlos Lorenzo*, MD; Ralph DeFronzo, MD (* early-stage investigators).
This pilot explores whether metformin in older adults with pre-diabetes prevents or slows the development of frailty.
PES-5: “mTOR inhibition in older subjects: Immune, cognitive and functional consequences”
Investigators: Dean Kellogg, MD, PhD; Ellen Kraig, PhD. This pilot explores whether treatment of elderly people with rapamycin and acarbose is safe, and whether such treatment mitigates immunologic, cognitive, and physical function phenotypes of aging.
A novel gene therapy to retard motor neuron degenerative disease and sarcopenia (Qitao Ran, PhD and Corinna Ross, PhD, Co-PIs)
The investigators seek to develop an adeno-associated viral vector expressing the Gpx4 gene, and then to test the effectiveness of transducing spinal motor neurons with the Gpx4 adeno-associated viral vector in retarding ALS and sarcopenia in mice and marmosets.
NAD Modulation to Improve Cognition in Mild Cognitive Impairment (MCI) (Becky Powers, MD, and Miranda Orr, PhD, Co-PIs)
NAD(+) can be synthesized from dietary intake of its precursors, including nicotinamide riboside, a currently available non-prescription nutritional supplement. In this pilot study, they will conduct an eight week, double-blind, randomized, placebo-controlled trial with this supplement. The investigators will then test the efficacy of NAD(+) supplementation on brain function through cognitive assessment and functional MRI.
Effect of Stress-Busting Program on Caregivers’ Quality of Life, Immunology/Stress Biomarkers and Cellular Aging (Lyda Arevalo-Flechas, PhD, PI and Chih-Ko Yeh, DDS, Co-I)
The proposed study examines the differences in quality of life (QoL), stress response, and immune function of Hispanic caregivers of persons with dementia, and aims to determine whether a caregiver intervention can effectively improve the QoL and immune function of Hispanic caregivers, including the measurement of the biological response to stress as indicated by immunologic and other pertinent protein markers in blood and saliva from the caregivers.
Feasibility of using the iron-chelator deferiprone on Mild Cognitive Impairment (MCI) (Donald Royall, MD and Dean Kellogg, MD, PhD, Co-PIs)
The investigators propose a single-blinded clinical trial to pilot the feasibility of using the iron-chelator deferiprone in cases of Mild Cognitive Impairment (MCI).
Completed Pilot Studies include:
PES-1: “Pilot study evaluating the pharmacokinetics and tolerability of metformin and acarbose in the marmoset”
Investigators: Elizabeth Fernandez*, PhD and Marty Javors, PhD (* early-stage investigator). This pilot explores whether marmosets tolerate treatment with either metformin or acarbose, and whether therapeutic blood levels of metformin are achievable in marmosets.
PES-2: “Methylene blue enhancement of fMRI brain activity, memory, and cognition in healthy aging and MCI”
Investigators: Peter Fox, MD; Donald Royall, MD, PhD; Francisco Gonzalez-Lima, PhD; Pavel Rodriguez*, MD; Andrew Bresnen*, PhD; Juan Gutierrez, MD (* early-stage investigators). This study explores whether methylene blue (MB) treatment enhances brain memory and cognitive function in elderly patients without and with mild cognitive impairment (MCI).
PES-4: “Lentiviral-mediated delivery of GDF11 in the marmoset”
Investigator: Senlin Li, MD. This study explores whetherl GDF (growth differentiation factor) 11, expressed from a transgene and secreted by blood cells, leads to the rejuvenation of brain, skeletal muscle, and heart of marmosets.
For information about human subject studies at UTHSCSA, you may visit: